ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1046

Comparison Of The Incidence Of Influenza Like Illness In Pregnant Women With Rheumatoid Arthritis and Women Without Rheumatoid Arthritis Who Receive An Influenza Vaccination

Yunjun Luo1, Diana L. Johnson2, Ronghui Xu3 and Christina D. Chambers1, 1Pediatrics, University of California, San Diego, La Jolla, CA, 2University of California San Diego Department of Pediatrics, La Jolla, CA, 3Family and Preventive Medicine, University of California, San Diego, La Jolla, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: autoimmune diseases, Infection, pregnancy, rheumatoid arthritis (RA) and vaccines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Influenza infection poses significant risk to pregnant women, therefore it is recommended that all pregnant women be vaccinated. However, it is unknown whether the protective effect of influenza vaccine is the same for pregnant women with rheumatoid arthritis (RA) as it is for pregnant women without autoimmune disease.

Methods:

Data were obtained from an ongoing prospective cohort study of pregnancy outcome among women in the U.S. and Canada. We included women enrolled between 2009 and 2012 who either had a current diagnosis of RA or were healthy women without autoimmune disease.   All women had completed multiple standard maternal telephone interviews during pregnancy that contained structured questions on the receipt of influenza vaccination and the occurrence of a diagnosis of influenza-like illness (ILI) during pregnancy.  Using time varying vaccine exposure during pregnancy, and adjusting for the timing of the flu season during pregnancy, we estimated the hazard ratio (HR) and its 95% confidence interval (CI) for ILI in a Cox regression model comparing women who reported receipt of an influenza vaccine some time in pregnancy to women without vaccine during pregnancy.  We addressed the potential differential effect of influenza vaccination on risk of ILI by testing an interaction term in the model (influenza vaccination by RA status).  For those women who were vaccinated, only ILI reported subsequent to vaccination was included as an event.

Results:

There were 1,233 subjects available for analysis: 825 women received influenza vaccine during pregnancy and 408 women did not receive vaccine; 245 women had RA and 988 women were without autoimmune disease.   Among RA subjects, 144 (58.8%) were vaccinated and among subjects without autoimmune disease, 681 (68.9%) were vaccinated. Nine (3.7%) of the women with RA and 55 (5.6%) of the women without autoimmune disease reported a diagnosis of ILI at some time in pregnancy.  Six (4.2%) vaccinated RA women and 28 (4.1%) vaccinated women without autoimmune disease reported ILI at some time in pregnancy. The adjusted HR for ILI in women vaccinated vs. women not vaccinated was 1.19 with 95% CI of 0.64, 2.24. The interaction term for vaccine exposure and autoimmune disease was not statistically significant (p = 0.16).

Conclusion:

We found no evidence of a difference in the incidence of ILI after vaccination is pregnant women with RA compared to women without autoimmune disease.


Disclosure:

Y. Luo,
None;

D. L. Johnson,

Abbott Laboratories,

2,

Amgen,

2,

UCB,

2,

Roche Genentech,

2,

Sanofi-Aventis Pharmaceutical,

2,

Bristol-Myers Squibb,

2,

Sandoz,

2,

Teva Pharmaceuticals,

2,

CSL,

2,

Apotex,

2,

Barr Laboratories, Inc.,

2,

Novartis Pharmaceutical Corporation,

2,

GSK,

2;

R. Xu,

Abbott Laboratories,

2,

Amgen,

2,

UCB,

2,

Roche Genentech,

2,

Sanofi-Aventis Pharmaceutical,

2,

Bristol-Myers Squibb,

2,

Sandoz,

2,

Teva Pharmaceuticals,

2,

Parr ,

2,

Apotex,

2,

Barr Laboratories, Inc.,

2,

Novartis Pharmaceutical Corporation,

2,

CSL,

2,

GSK,

2;

C. D. Chambers,

Abbott Laboratories,

2,

Amgen,

2,

UCB,

2,

Roche Genentech,

2,

Sanofi-Aventis Pharmaceutical,

2,

Bristol-Myers Squibb,

2,

Sandoz,

2,

Teva Pharmaceuticals,

2,

Parr ,

2,

Apotex,

2,

Barr Laboratories, Inc.,

2,

CSL,

2,

GSK,

2,

Novartis Pharmaceutical Corporation,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-the-incidence-of-influenza-like-illness-in-pregnant-women-with-rheumatoid-arthritis-and-women-without-rheumatoid-arthritis-who-receive-an-influenza-vaccination/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology